Remove Molecular Biology Remove Protein Expression Remove Vaccine
article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News at Mary Ann Liebert, Inc.

article thumbnail

Enhancing gene therapy with Circio

Drug Target Review

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

article thumbnail

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

The Phase II clinical trial will evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer. UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Mogrify – U.K.-based